Loading…
Metagenomi Therapeutics, Inc. is projected to rise to $1.25 by 2027, a +3% move from its current price of $1.21. MGX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.19 | $1.21 | $1.23 | +0.02% |
| Aug 6 | $1.18 | $1.21 | $1.25 | +0.03% |
| Aug 7 | $1.17 | $1.21 | $1.25 | +0.05% |
| Aug 8 | $1.16 | $1.21 | $1.26 | +0.07% |
| Aug 9 | $1.16 | $1.21 | $1.27 | +0.09% |
| Aug 10 | $1.15 | $1.21 | $1.27 | +0.10% |
| Aug 11 | $1.15 | $1.21 | $1.28 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.15 | $1.21 | $1.28 | +0.12% |
| Week 2 | $1.13 | $1.21 | $1.31 | +0.24% |
| Week 3 | $1.11 | $1.21 | $1.33 | +0.36% |
| Week 4 | $1.09 | $1.22 | $1.35 | +0.48% |
| Week 5 | $1.08 | $1.22 | $1.37 | +0.60% |
| Week 6 | $1.07 | $1.22 | $1.39 | +0.72% |
| Week 7 | $1.06 | $1.22 | $1.40 | +0.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Metagenomi Therapeutics, Inc. is an in vivo genome editing company focused on developing curative genetic medicines in the United States. Its lead development program MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia.
The company collaborates with Ionis Pharmaceuticals, Inc. on programs spanning apolipoprotein C-III for hypertriglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. It was formerly known as Metagenomi, Inc.
and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
MGX trades as Metagenomi Therapeutics, Inc. The current price is $1.21, the market capitalization is $45.36M, and its rank is 4369.
The near-term price action shows a 30-day range from $1.05 to $1.39, with a BEARISH sentiment, RSI(14) at 40, SMA50 at $1.27 and SMA200 at $1.64. A support level sits at $1.14 and a resistance at $1.32.
The longer-term forecast points to a shift from neutral to bullish over time, with the average price rising to $1.69 by 2032 and $4.05 by 2050, and the maximum forecast climbing to $6.89 by 2050. The projected ROI expands from single-digit figures in the nearer years to a headline 235.9% by 2050, signaling substantial upside potential in the late horizon.
A major floor 8.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.7% away) — a key level to hold.
The nearest ceiling, 9.1% above — a clean break opens room to run.
A major ceiling 26.4% above — clearing it would confirm fresh momentum.
Key MGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.21 | Buy | $1.21 | Buy |
| MA 10 | $1.21 | Sell | $1.22 | Sell |
| MA 20 | $1.25 | Sell | $1.23 | Sell |
| MA 50 | $1.26 | Sell | $1.27 | Sell |
| MA 100 | $1.34 | Sell | $1.35 | Sell |
| MA 200 | $1.59 | Sell | $1.56 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.94 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -111.60 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -7.75 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.11 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 22.86 | Buy |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 1.21 | Buy |
| ADX (14) | 11.77 | Neutral |
| ATR (14) | 0.02 | Info |
The near-term technical picture is BEARISH. The RSI14 is 40, and the stock sits around the SMA50 of $1.27 versus the SMA200 of $1.64.
A defined support level sits at $1.14 and a resistance at $1.32, framing the immediate trade range. The 30-day price range runs from $1.05 to $1.39, with volatility measured at 40% annually.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.14 | $1.21 | $1.53 | 0% | Neutral | |
| $1.02 | $1.25 | $1.60 | +3% | Neutral | |
| $1.02 | $1.27 | $1.67 | +5% | Neutral | |
| $1.06 | $1.34 | $1.81 | +11% | Neutral | |
| $0.983 | $1.27 | $1.74 | +5% | Neutral | |
| $1.07 | $1.40 | $1.96 | +16% | Neutral | |
| $1.29 | $1.70 | $2.41 | +41% | Bullish | |
| $1.28 | $1.71 | $2.46 | +41% | Bullish | |
| $1.32 | $1.78 | $2.59 | +47% | Bullish | |
| $1.32 | $1.80 | $2.66 | +49% | Bullish | |
| $1.81 | $2.58 | $3.99 | +113% | Bullish | |
| $2.68 | $4.13 | $6.88 | +242% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.14 | $1.21 | $1.48 | +0.00% |
| September 2026 | $1.06 | $1.24 | $1.49 | +2.88% |
| October 2026 | $1.04 | $1.23 | $1.49 | -1.28% |
| November 2026 | $1.05 | $1.25 | $1.52 | +1.38% |
| December 2026 | $1.05 | $1.25 | $1.53 | +0.06% |
Click any year to see its month-by-month MGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect MGX to range from $1.14 to $1.53 through 2026. The $1.21 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The MGX price prediction for 2027 points to an average of $1.25 (low $1.02, high $1.60) — a potential gain of +3% on today's $1.21. Price action looks broadly range-bound.
In 2028, MGX is projected to trade between $1.02 and $1.67, averaging $1.27 — a potential gain of +5% from today's $1.21. That is up +1% on the projected 2027 average. A consolidation phase looks the most probable path here.
Metagenomi Therapeutics, Inc.'s 2029 outlook centres on $1.34, within a $1.06 to $1.81 range. That is up +6% on the projected 2028 average. That marks a +11% change versus current levels. Price action looks broadly range-bound.
By 2030, MGX could reach as high as $1.74, with a base case around $1.27 and support toward $0.983 — roughly +5% from $1.21. A consolidation phase looks the most probable path here.
Expect MGX to range from $1.07 to $1.96 through 2031. The $1.40 average target implies a +16% move from current prices. That is up +11% on the projected 2030 average. Price action looks broadly range-bound.
The MGX price prediction for 2032 points to an average of $1.70 (low $1.29, high $2.41) — a potential gain of +41% on today's $1.21. Buyers look set to stay in control over this stretch.
In 2033, MGX is projected to trade between $1.28 and $2.46, averaging $1.71 — a potential gain of +41% from today's $1.21. That is up +1% on the projected 2032 average. Momentum favours further upside here.
Metagenomi Therapeutics, Inc.'s 2034 outlook centres on $1.78, within a $1.32 to $2.59 range. That is up +4% on the projected 2033 average. That marks a +47% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, MGX could reach as high as $2.66, with a base case around $1.80 and support toward $1.32 — roughly +49% from $1.21. Momentum favours further upside here.
Expect MGX to range from $1.81 to $3.99 through 2040. The $2.58 average target implies a +113% move from current prices. That is up +43% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The MGX price prediction for 2050 points to an average of $4.13 (low $2.68, high $6.88) — a potential gain of +242% on today's $1.21. Momentum favours further upside here.
Investing $1,000 in MGX today (≈ 826.446281 MGX) could be worth
$3,415.43
+$2,415.43 (+242%) by 2050 · US Dollar
Based on the average projected MGX price of $4.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MGXwould be worth at today's price.
$1,000 invested in MGX on Jul 31, 2025 (≈ 434.782618 MGX) would be worth
$526.09
-$473.91 (-47.4%) today · 0.53× · US Dollar
Based on a MGX entry price of $2.3 vs. today's $1.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.21 | $1,004.15 | +0.4% |
| 1 month ago | $1.21 | $1,000 | -0.0% |
| 3 months ago | $1.39 | $870.5 | -12.9% |
| 6 months ago | $1.54 | $785.71 | -21.4% |
| 1 year ago | $2.3 | $526.09 | -47.4% |
| All time (2.5y) ago | $10.31 | $117.36 | -88.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MGX forecast.
Our base-case forecast reaches $2.40 around 2040.
Implied market cap at $2.40: $90.35M
Over the multi-year horizon, the forecast transitions from neutral in the early years to bullish in the later years. The average price is projected to rise from $1.69 in 2032 to $4.05 by 2050, with the max forecast reaching $6.89 in 2050.
Key steps along the way show 2032 with avg $1.69, max $2.42 (ROI 39.9%), 2033 with avg $1.70, max $2.47 (ROI 40.7%), 2034 with avg $1.77, max $2.62 (ROI 47.1%), and 2035 with avg $1.78, max $2.67 (ROI 48%). By 2040 the forecast envisions avg $2.58, max $4.07 (ROI 114.2%), culminating in 2050 with avg $4.05, max $6.89 (ROI 235.9%).
These figures illustrate a pronounced long-run upside potential, though they are estimates and not guarantees. Investors should consider the uncertainty inherent in future market conditions when interpreting these forecasts.
Tap a question to reveal the answer.
Forecasts for 2030 show min $0.9665, avg $1.26, max $1.75 with ROI 4.3% and neutral sentiment.
Near-term sentiment is neutral through 2029, with rising upside later in the forecast. By 2032 the average price is $1.69 with ROI 39.9%, increasing to an average of $4.05 and ROI 235.9% by 2050; these are estimates, not guarantees.
Yes. The 2034 forecast lists a max of $2.62 (min $1.30, avg $1.77, ROI 47.1%). The path continues with higher tops in later years.
Current price is $1.21 and market cap is $45.36M.
The 2050 forecast shows min $2.56, avg $4.05, max $6.89 with ROI 235.9% and sentiment BULLISH.
Metagenomi Therapeutics, Inc. Community Discussion
0Share your Metagenomi Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.